GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Syndax Pharmaceuticals Inc (NAS:SNDX) » Definitions » Change In Other Working Capital

SNDX (Syndax Pharmaceuticals) Change In Other Working Capital : $4.74 Mil (TTM As of Mar. 2025)


View and export this data going back to 2016. Start your Free Trial

What is Syndax Pharmaceuticals Change In Other Working Capital?

Syndax Pharmaceuticals's Change In Other Working Capital for the quarter that ended in Mar. 2025 was $-7.04 Mil. It means Syndax Pharmaceuticals's Other Working Capital declined by $7.04 Mil from Dec. 2024 to Mar. 2025 .

Syndax Pharmaceuticals's Change In Other Working Capital for the fiscal year that ended in Dec. 2024 was $12.46 Mil. It means Syndax Pharmaceuticals's Other Working Capital increased by $12.46 Mil from Dec. 2023 to Dec. 2024 .

Syndax Pharmaceuticals Change In Other Working Capital Historical Data

The historical data trend for Syndax Pharmaceuticals's Change In Other Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Syndax Pharmaceuticals Change In Other Working Capital Chart

Syndax Pharmaceuticals Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Change In Other Working Capital
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.52 -13.13 -3.47 10.71 12.46

Syndax Pharmaceuticals Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Change In Other Working Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.32 -0.32 0.46 11.63 -7.04

Syndax Pharmaceuticals Change In Other Working Capital Calculation

Change In Other Working Capital is any increase or decrease between periods of other working capital that are not otherwise classified.

Change In Other Working Capital for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $4.74 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Syndax Pharmaceuticals Change In Other Working Capital Related Terms

Thank you for viewing the detailed overview of Syndax Pharmaceuticals's Change In Other Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Syndax Pharmaceuticals Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Syndax Pharmaceuticals Inc (NAS:SNDX) » Definitions » Change In Other Working Capital
Comparable Companies
CRMD QURE PHVS ELVN ZYME LENZ SYRE NUVB NAGE WVE VRTX ASX:CSL REGN XKRX:207940 ALNY XBRU:ARGX XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
1T3:Germany
Address
730 Third Avenue, 9th Floor, New York, NY, USA, 10017
Website
https://www.syndax.com
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.
Executives
Keith Katkin director C/O UROVANT SCIENCES, INC., 5281 CALIFORNIA AVENUE, SUITE 100, IRVINE CA 92617
Huber Martin H. Jr. director C/O TESARO, INC., 1000 WINTER STREET, SUITE 3300, WALTHAM MA 02451
Michael A Metzger officer: President and COO C/O SYNDAX PHARMACEUTICALS, INC., 400 TOTTEN POND ROAD,, WALTHAM MA 02451
Neil Gallagher officer: President, Head of R&D 35 GATEHOUSE DRIVE, BUILDING D, FLOOR 3, WALTHAM MA 02451
Keith A. Goldan officer: Chief Financial Officer 227 WASHINGTON STREET, SUITE 200, CONSHOHOCKEN PA 19428
Briggs Morrison director, officer: Chief Executive Officer C/O SYNDAX PHARMACEUTICALS, INC., 400 TOTTEN POND ROAD, SUITE 110, WALTHAM MA 02451
William Meury director C/O FOREST LABORATORIES, INC., 909 THIRD AVENUE, NEW YORK NY 10022
Peter Ordentlich officer: Chief Technology Officer C/O SYNDAX PHARMACEUTICALS, INC., 400 TOTTEN POND ROAD, SUITE 140, WALTHAM MA 02451
Pierre Legault director P.O. BOX 1028, C/O STONE MANAGEMENT LLC, BERWYNE PA 19312
Steve M Sabus officer: Chief Commercial Officer 10628 SCIENCE CENTER DRIVE, SUITE 200, SAN DIEGO CA 92121
Dennis Podlesak director C/O PENINSULA PHARMACEUTICALS, INC., 1751 HARBOR BAY PARKWAY, ALAMEDA CA 94502
Catherine Madigan officer: Chief Medical Officer 35 GATEHOUSE DRIVE, BUILDING D, FLOOR 3, WALTHAM MA 02451
Alexander Nolte officer: Chief Accounting Officer 35 GATEHOUSE DRIVE, BUILDING D, FLOOR 3, WALTHAM MA 02451
Fabrice Egros director C/O SYNDAX PHARMACEUTICALS, INC., TOTTEN POND ROAD, SUITE 140, WALTHAM MA 02451
Daphne Karydas officer: Chief Financial Officer 35 GATEHOUSE DRIVE, BUILDING D, FLOOR 3, WALTHAM MA 02451